MP Biomedicals and Rusnano have signed a research and development agreement of cooperation for the production of innovative pharmaceuticals, including personal pharmacogenetic treatments.
The companies plan to jointly implement projects focused on anti-aging and increasing life expectancy, as well as create the infrastructure for innovations in the area of nanobiotechnology.
Areas of cooperation include scientific research, coordinating with other groups and expert commissions.
Both companies have also decided to jointly provide mutual methodological and scientific-medical support for studies in the area of nanotechnology.
MP Biomedicals and Rusnano will additionally collaborate on creating the information infrastructure to ensure the establishment and support of databases related to scientific and medical developments, along with innovative projects in the field of biotechnology, pharmaceutical industry and nanotechnology.
Both companies are expected to elaborate the long-term forecast for areas of nanotechnology applications in the field of life sciences and pharmaceutics, with the allocation of promising emerging markets, products and services, as well as a list of priorities and critical technologies in the pharmaceutical industry.
